A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma

医学 中性粒细胞减少症 不利影响 内科学 细胞因子释放综合征 耐火材料(行星科学) 胃肠病学 多发性骨髓瘤 发热性中性粒细胞减少症 外科 毒性 免疫疗法 癌症 嵌合抗原受体 天体生物学 物理
作者
Anita D’Souza,Nina Shah,Cesar Rodriguez,Peter M. Voorhees,Katja Weisel,Orlando F. Bueno,Rajvineeth Kumar Pothacamury,Kevin J. Freise,Susan Yue,Jeremy A. Ross,Akshanth R. Polepally,Chetasi Talati,Shane Lee,Ziyi Jin,Ben Buelow,Ravi Vij,Shaji Kumar
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:40 (31): 3576-3586 被引量:107
标识
DOI:10.1200/jco.22.01504
摘要

PURPOSE ABBV-383, a B-cell maturation antigen × CD3 T-cell engaging bispecific antibody, has demonstrated promising results in an ongoing first-in-human phase I study (ClinicalTrials.gov identifier: NCT03933735 ) in patients with relapsed/refractory multiple myeloma (RRMM). Herein, we report safety and efficacy outcomes of this phase I dose escalation/expansion study. METHODS Patients with RRMM (≥ three prior lines including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody) were eligible. ABBV-383 was administered intravenously over 1-2 hours once every 3 weeks, without any step dosing. A 3 + 3 design with backfilling for dose escalation was used (intrapatient escalation to highest safe dose permitted) followed by initiation of dose expansion. RESULTS As of January 8, 2022, 124 patients (dose escalation [0.025-120 mg], n = 73; dose expansion [60 mg], n = 51) have received ABBV-383; median age was 68 years (range, 35-92 years). The most common hematologic treatment-emergent adverse events (TEAEs) were neutropenia (all grades: 37%) and anemia (29%). The most common nonhematologic TEAEs were cytokine release syndrome (57%) and fatigue (30%). Seven deaths from TEAEs were reported with all considered unrelated to study drug by the investigator. For all efficacy-evaluable patients (n = 122; all doses), the objective response rate (ORR) was 57% and very good partial response (VGPR) or better (≥ VGPR) rate was 43%. In the 60 mg dose expansion cohort (n = 49), the ORR and ≥ VGPR rates were 59% and 39%, respectively; and in the ≥ 40 mg dose escalation plus dose expansion cohorts (n = 79) were 68% and 54%, respectively. CONCLUSION ABBV-383 in patients with RRMM was well tolerated with an ORR of 68% at doses ≥ 40 mg. This novel therapy's promising preliminary antitumor activity in heavily pretreated patients warrants further clinical evaluation.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
烨采发布了新的文献求助10
1秒前
1秒前
1秒前
1秒前
1秒前
zumrat完成签到,获得积分20
2秒前
2秒前
月白发布了新的文献求助20
2秒前
关心完成签到,获得积分10
3秒前
深情安青的应助被开心德地采纳,获得10
3秒前
太阳照常升起完成签到 ,获得积分10
4秒前
4秒前
hu完成签到,获得积分10
4秒前
5秒前
5秒前
5秒前
彭于晏的应助被势不可挡采纳,获得10
5秒前
顺意完成签到 ,获得积分20
6秒前
yuanquaner完成签到,获得积分10
6秒前
纪十三发布了新的文献求助10
7秒前
关心发布了新的文献求助10
7秒前
大模型的应助被amo采纳,获得10
8秒前
丘比特的应助被哈哈哈采纳,获得30
8秒前
8秒前
李健的应助被唐璜采纳,获得10
9秒前
温文文发布了新的文献求助10
9秒前
yy完成签到 ,获得积分10
9秒前
9秒前
11完成签到 ,获得积分10
9秒前
10秒前
kkkk发布了新的文献求助10
10秒前
dlm关注了科研通微信公众号
10秒前
bkagyin的应助被开心德地采纳,获得50
11秒前
13秒前
wangchen完成签到,获得积分10
13秒前
今后的应助被非躺平人生采纳,获得10
13秒前
14秒前
今后的应助被执着采纳,获得10
15秒前
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187835
求助须知:如何正确求助?哪些是违规求助? 9575825
关于积分的说明 21843558
捐赠科研通 7785715
什么是DOI,文献DOI怎么找? 3435125
关于科研通互助平台的介绍 2559495
邀请新用户注册赠送积分活动 2482008